| (AIM: SAR) | 17 December 2014 |
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Result of Annual General Meeting
Sareum (AIM: SAR), the specialist cancer drug discovery and development business, announces that at the Company's Annual General Meeting held earlier today, all resolutions were duly passed.
| Sareum Holdings plc | |
| Tim Mitchell | 01223 497 700 |
| Sanlam Securities UK Limited (Nomad) | |
| Simon Clements | 020 7628 2200 |
| Hybridan LLP (Broker) | |
| Claire Noyce / William Lynne | 020 3713 4581 / 4582 |
| The Communications Portfolio (Media enquiries) | |
| Ariane Comstive [email protected] | 07785 922 354 |
Notes for editors:
About Sareum Holdings plc
Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.
SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SAREUM HOLDINGS PLC via Globenewswire